Background: This article presents an exploration of naturally occurring Class-A magic mushroom markets in the UK. It aims to challenge some of the mainstream narratives about drug markets and to identify features of this specific market, which will extend our understanding of how illegal drug markets operate and are structured more generally.
Methods: The research presented comprises a three year ethnography of sites of magic mushroom production in rural Kent. Observations were conducted at 5 research sites over three consecutive magic mushroom seasons and interviews were conducted with 10 (8 male; 2 female) key informants.
Results: It finds that naturally occurring magic mushroom sites are reluctant and liminal sites of drug production, distinct from other Class-A drug production sites due to their: open and accessible nature; lack of invested ownership or evidence of purposeful cultivation; and lack of law enforcement disruption efforts, violence or organised crime involvement. Seasonal magic mushroom picker participants were found to be a sociable group, often acting in a cooperative nature, and without evidence of territoriality or violent dispute resolution. These findings have wider application in challenging the dominant narrative that the most harmful (Class-A) drug markets are homogenous in their violent, profit driven, hierarchical nature, and most Class-A drug producers/suppliers are morally corrupt, financially motivated and organised.
Conclusion: A greater understanding of the variety of Class-A drug markets in operation can challenge archetypes and discrimination in understanding drug market involvement, will allow the development of more nuanced policing and policy strategies, and contributes to the presentation of a fluidity of drug market structure that permeates beyond bottom level street markets or social supply.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.drugpo.2023.103973 | DOI Listing |
Int J Med Mushrooms
December 2024
National Center for Natural Products Research, Division of Pharmacognosy, Department of BioMolecular Sciences, School of Pharmacy, University of Mississippi, University, MS 38677, USA.
The psychedelic mushroom market has expanded rapidly due to changing regulations and increasing consumer demand. Product diversity now extends beyond traditional capsules and tablets to include gummies, powders, and confectionery items, complicating quality control efforts. To assess the quality and potential adulteration of Amanita musca-ria and Psilocybe cubensis-based products, a validated LC-QToF-MS method was developed.
View Article and Find Full Text PDFJ Psychoactive Drugs
November 2024
Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran.
Psilocybin-containing mushrooms, commonly known as magic mushrooms, drastically affect mental processing, cognitive functioning, and the mood state. In the present study, we investigated the effect of the extract on spatial memory and the brain-derived neurotrophic factor (BDNF) in rats exposed to chronic unpredictable mild stress (CUMS). The duration of CUMS was 4 weeks.
View Article and Find Full Text PDFNat Prod Res
November 2024
Department of Microbiology, Bharathidasan University, Tiruchirappalli, India.
Psychedelic mushrooms belonging to basidiomycota have gained prominence in research due to the range of hallucinogenic compounds. To combat the challenge of antimicrobial resistance, exploring alternative antimicrobial peptides has become crucial. In this study, we present the proteomic analysis of psychedelic mushroom.
View Article and Find Full Text PDFChembiochem
December 2024
Institute for General, Inorganic and Theoretical Chemistry, University of Innsbruck, Innrain 80-82, Innsbruck, 6020, Austria.
The Psilocybe cubensis SAM-dependent methyltransferase, PsiM, catalyzes the last step in the biosynthesis of psilocybin. Likely evolved from monomethylating RNA methyltransferases, PsiM acquired a key amino acid exchange in the secondary sphere of the active site, M247 N, which is responsible for its capacity to dimethylate. Two variants, PsiM and PsiM, were generated to further examine the role of Asn247 for mono- and dimethylation in PsiM.
View Article and Find Full Text PDFJ Psychoactive Drugs
September 2024
Center of Excellence for Environmental Health & Toxicology, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand.
Psilocybin, a major indole alkaloid found in magic mushrooms (), has recently drawn attention as a breakthrough therapy to treat major depressive disorder. This review aimed to summarize and identify knowledge gaps concerning their pharmacokinetic characteristics of psilocybin and its active metabolite, psilocin. Original studies related to pharmacokinetics of psilocybin conducted , animals, and humans were systematically collected from PubMed, Scopus, and ScienceDirect, from their inceptions to November 2023.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!